SCHEMBL6012016

SCHEMBL6012016

O=C(CN1CCOCC1)N1CCC(/C=C/c2cccc(Cl)c2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.46
MEN1 O00255 3/20 0.46
TSHR P16473 3/20 0.46
MAPT P10636 1/20 0.45
FKBP1A P62942 1/20 0.45
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44
NPC1 O15118 1/20 0.44
ALOX15 P16050 1/20 0.44
HSD17B10 Q99714 1/20 0.44
NAMPT P43490 1/20 0.42
MAPK1 P28482 2/20 0.41
HDAC8 Q9BY41 1/20 0.41
USP2 O75604 1/20 0.41
KDM4E B2RXH2 1/20 0.40
TP53 P04637 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ADAMTS5 Q9UNA0 1/20 0.40
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14261804 0.88 NPC1 (0.46) KMT2AMEN1TSHRMAPTALDH1A1
SCHEMBL14261811 0.87 HTT (0.47) KMT2ATSHRALDH1A1ALOX15HSD17B10
SCHEMBL10069273 0.87 TSHR (0.44) KMT2AMEN1TSHRMAPTALDH1A1
SCHEMBL6009399 0.87 MAOA (0.54) TSHRMAPTALDH1A1NPC1ALOX15
SCHEMBL10069075 0.87 MAPT (0.47) TSHRMAPTALDH1A1LMNANPC1
SCHEMBL6011048 0.87 ALDH1A1 (0.47) KMT2AMEN1TSHRALDH1A1LMNA
SCHEMBL14261824 0.87 HTT (0.47) KMT2ATSHRALDH1A1ALOX15HSD17B10
SCHEMBL14261820 0.87 MAOA (0.54) TSHRMAPTALDH1A1NPC1ALOX15
SCHEMBL6011799 0.87 TSHR (0.44) KMT2AMEN1TSHRMAPTALDH1A1
SCHEMBL6011003 0.87 TSHR (0.44) KMT2AMEN1TSHRMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1785415-B1 PIPERIDINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ASTELLAS PHARMA INC (JP) 2012-05-02 EP disclosed
US-20080070898-A1 Piperidine Derivative or Pharmaceutically Acceptable Salt Thereof ASTELLAS PHARMA INC. (JP) 2008-03-20 US disclosed
US-20080070898-A1 Piperidine Derivative or Pharmaceutically Acceptable Salt Thereof ASTELLAS PHARMA INC. (JP) 2008-03-20 US disclosed
EP-1785415-A1 PIPERIDINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Astellas Pharma Inc. (JP) 2007-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070898-A1 Piperidine Derivative or Pharmaceutically Acceptable Salt Thereof TRPV1, TRPA1, CACNA1D KMT2A 722/4885MEN1 2489/4885TSHR 4110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.